Higher levels of HIF2α found to slow down aggressive childhood cancer
When the researchers increased the amount of HIF2α in neuroblastoma cells with many copies of the MYCN gene, they observed a significant reduction in MYCN protein levels. Read more: https://medicalxpress.com/news/2025-10-higher-hif2-aggressive-childhood-cancer.html
Nov 18
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
First late effects study since new treatments were introduced found high prevalence of hearing loss, growth failure, underweight and lung disease. Read more: https://www.eurekalert.org/news-releases/1102637
Nov 14
Researchers develop a new approach for treating children with neuroblastoma
A research team from the University of Zurich and the University Children's Hospital Zurich has developed a new approach for treating children with malignant tumors of the nervous system. By combining an approved drug with a specialized diet, they were able to slow down tumor growth and stimulate cancer cells to mature into normal nerve cells. Read more: https://www.news-medical.net/news/20251021/Researchers-develop-a-new-approach-for-treating-children-with-neuroblastoma.aspx
Nov 13
Pesticides used near farm communities tied to rare but deadly childhood cancer
Children whose mothers lived near farms and fields treated with certain pesticides during pregnancy have a higher risk of a deadly cancer that is most commonly found in infants before their first birthday, according to a new study. Read more: https://www.thenewlede.org/2025/10/pesticides-child-cancer-california/
Nov 12
AMXT 1501 and DFMO Combination Achieve FDA Orphan Drug Designation
The FDA has granted orphan drug designation (ODD) to AMXT 1501 in combination with difluoromethylornithine (Iwilfin; DFMO) for the treatment of patients with neuroblastoma. Read more: https://www.targetedonc.com/view/amxt-1501-and-dfmo-combination-achieve-fda-orphan-drug-designation
Nov 6
Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment
"Even though naxitamab appeared to have erased the cancer, Dr. Modak wanted to do everything possible to prevent the high-risk neuroblastoma from returning. He proposed that James receive a pioneering treatment: a cancer vaccine that would train his immune system to continuously be on guard to spot and fight malignant cells." Read more: https://www.mskcc.org/news/cancer-vaccine-could-prevent-neuroblastoma-from-returning-after-antibody-treatment
Oct 28
Potential new treatment strategy for high-risk neuroblastoma
The study found that restricting the cancer’s access to an essential nutrient called arginine yielded promising results, both when used on its own and when used in combination with standard therapies. Read more: https://www.ccia.org.au/blog/potential-new-treatment-strategy-for-high-risk-neuroblastoma
Oct 14
ecDNA discovery targets ‘zombie’ cells in childhood cancers
Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant...
Oct 3
Breakthrough Study Finds Key Mechanism Driving Neuroblastoma Progression
A groundbreaking study led by Children’s Hospital Los Angeles has found a novel mechanism behind neuroblastoma progression: the shape and...
Sep 10
Some cancer cells just won't commit: Why that might be good news for neuroblastoma patients
Identifying why some patients regress and others don't could help thousands of patients. [...] In mice bred to have tumors that were...
Sep 3

